Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review

INTRODUCTION: Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic drugs is increasingly influencing revised recommendations for second-line therapy in type 2 diabetes (T2D). This systematic review aimed to compare the cost-effectiveness of newer antidiabetic drugs specified as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jiejin, Zhou, Ying, Li, Qingyu, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499965/
https://www.ncbi.nlm.nih.gov/pubmed/37515713
http://dx.doi.org/10.1007/s12325-023-02612-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499965/
https://www.ncbi.nlm.nih.gov/pubmed/37515713
http://dx.doi.org/10.1007/s12325-023-02612-z

Ejemplares similares